 | Up a level |
Pabst, Thomas; Papayannidis, Cristina; Demirkan, Fatih; Doronin, Vadim; Fogliatto, Laura M; Guttke, Christina; Gyan, Emmanuel; Hamad, Nada; Herrera, Pilar; Hultberg, Anna; Jacobs, Julie; Johnson, Amy J; Langlois, Angélique; Ma, Xuewen; Martinelli, Giovanni; Arnan, Montserrat; Müller, Rouven; Nottage, Kerri; Ofran, Yishai; Özcan, Muhit; ... (2023). Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. The Lancet. Haematology, 10(11), e902-e912. Elsevier 10.1016/S2352-3026(23)00207-7
Pleyer, Lisa; Leisch, Michael; Kourakli, Alexandra; Padron, Eric; Maciejewski, Jaroslaw Pawel; Xicoy Cirici, Blanca; Kaivers, Jennifer; Ungerstedt, Johanna; Heibl, Sonja; Patiou, Peristera; Hunter, Anthony Michael; Mora, Elvira; Geissler, Klaus; Dimou, Maria; Jimenez Lorenzo, Maria-José; Melchardt, Thomas; Egle, Alexander; Viniou, Athina-Nora; Patel, Bhumika Jayantibhai; Arnan, Montserrat; ... (2021). Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. The Lancet. Haematology, 8(2), e135-e148. Elsevier 10.1016/S2352-3026(20)30374-4
